Indian drug maker, Dr Reddy's Laboratories Ltd, has announced that it has launched Reddy-Lenalidomide, a generic equivalent to Revlimid (lenalidomide) capsules in Canada.

The firm said that the launch came after the drug was approved by Health Canada. Reddy-Lenalidomide is claimed to be one of the first generic medications of its kind to be launched in Canada. It is used to treat patients with transfusion-dependent anaemia due to Low or lntermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality. Approval for the drug was provided based on red blood cell transfusion independence response rates. However, overall survival benefit has not been demonstrated.

Reddy-Lenalidomide can also be administered in combination with dexamethasone in multiple myeloma patients who are not eligible for stem cell transplant.